Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study (Q40349700)

19 September 2017

title

Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study (English)

1 reference

mild cognitive impairment

19 September 2017

0 references

0 references

1 reference

inferred from title

cognitive dysfunction

1 reference

1

1 reference

19 September 2017

2

Henrik Zetterberg

1 reference

19 September 2017

5

Kaj Blennow

1 reference

19 September 2017

4

Elisabet Londos

1 reference

19 September 2017

6

Lennart Minthon

1 reference

19 September 2017

3

Peder Buchhave

1 reference

19 September 2017

publication date

1 March 2006

1 reference

19 September 2017

1 reference

19 September 2017

volume

5

1 reference

19 September 2017

issue

3

1 reference

19 September 2017

page(s)

228-234

1 reference

Global prevalence of dementia: a Delphi consensus study

19 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970355-6

7 January 2021

Tangles and plaques in nondemented aging and "preclinical" Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970355-6

7 January 2021

Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970355-6

7 January 2021

Mild cognitive impairment as a diagnostic entity

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970355-6

7 January 2021

CSF markers for incipient Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970355-6

7 January 2021

Looking Backward to Move Forward: Early Detection of Neurodegenerative Disorders

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970355-6

7 January 2021

Back to the future: the 'old-fashioned' way to new medications for neurodegeneration

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970355-6

7 January 2021

Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970355-6

7 January 2021

Cerebrospinal fluid tau protein and periventricular white matter lesions in patients with mild cognitive impairment: implications for 2 major pathways

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970355-6

7 January 2021

Empirical evidence of design-related bias in studies of diagnostic tests

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970355-6

7 January 2021

Guidelines for meta-analyses evaluating diagnostic tests.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970355-6

7 January 2021

Use of methodological standards in diagnostic test research. Getting better but still not good.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970355-6

7 January 2021

Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970355-6

7 January 2021

Tau suppression in a neurodegenerative mouse model improves memory function

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970355-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970355-6

1 reference

7 January 2021

The ten point clock test: a quick screen and grading method for cognitive impairment in medical and surgical patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970355-6

7 January 2021

Mild cognitive impairment: clinical characterization and outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970355-6

7 January 2021

Silent brain infarcts and the risk of dementia and cognitive decline

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970355-6

7 January 2021

Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer's disease?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970355-6

7 January 2021

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970355-6

7 January 2021

Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970355-6

7 January 2021

Report of the second dementia with Lewy body international workshop: diagnosis and treatment. Consortium on Dementia with Lewy Bodies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970355-6

7 January 2021

Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970355-6

7 January 2021

Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970355-6

7 January 2021

Index for rating diagnostic tests

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970355-6

7 January 2021

Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970355-6

7 January 2021

CSF Abeta42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970355-6

7 January 2021

The incidence of dementia: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970355-6

7 January 2021

Advances in the early detection of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970355-6

7 January 2021

Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970355-6

7 January 2021

Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970355-6

7 January 2021

Cerebrospinal fluid beta-amyloid 42 is reduced before the onset of sporadic dementia: a population-based study in 85-year-olds

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970355-6

7 January 2021

Familial Alzheimer disease: decreases in CSF Abeta42 levels precede cognitive decline.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970355-6

7 January 2021

Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970355-6

7 January 2021

Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970355-6

7 January 2021

Patterns of brain activation in people at risk for Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970355-6

7 January 2021

A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970355-6

7 January 2021

Vitamin E and donepezil for the treatment of mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970355-6

7 January 2021

Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2806%2970355-6

7 January 2021

10.1016/S1474-4422(06)70355-6

Identifiers

DOI

1 reference

19 September 2017

1 reference